Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
AB1
AB2
Acyclovir : EC
1
0.5
500
10
-
Poloxamer407 (mg)
Methyl alcohol (ml)
DCM (ml)
Acetone (ml)
DMSO (ml)
Diethyl ether (ml)
Deionized water (ml)
100
AB3
AB4
AB5
AB6
AB7
AB8
1
1
1
0.5
0.5
0.5
500
500
500
10
10
10
100
100
100
Physiochemical parameters
1
0.5
500
10
100
1
0.5
500
10
100
1
1
500
10
100
1
2
500
10
100
245
165
250
270
300
169
173
180
-40.23
-45.75
-49.61
-41.84
-40.61
-42.33
-41.51
-45.64
80.41.1
73.20.5
78.11.5
68.60.1
78.11.3
80.80.2
82.01.0
84.20.7
Entrapment
efficiency* (%)
*Mean SD, n=3.
83
Parameters
Cmax (g/mL)
Tmax (h)
T1/2 (h)
AUC (g/ml*h)
AUMC (g/ml*h^2)
MRT (h)
Clearances ((g/ml)/h)
Oral Solution
(20 mg/kg)
0.98
1
2.79
2.94
12.86
3.84
5.98
R7
58
4
0.9
34.3
27
***
Clear
NLTIOG
(10 mg/kg)
1.92
4
27.30
25.47
2098.04
38.68
0.18
40300
R1
35300
R2
30300
R3
25300
R4
20300
R5
14
12
10
8
6
4
2
0
R6
R7
NLTIOG Formulation code
R6
15300
16
Spreadability (gm.cm/sec)
R7
10300
140000
300
0
20
40
60
Temperature (C)
Figure-2: Temperature-dependent changes of the
elasticity modulus
200
5300
120000
100000
80000
60000
40000
20000
0
R6
Time in seconds
150
R7
50
0
R6
R7
100
90
80
70
60
50
40
AB7
AB8
30
20
10
0
0
10
20
30
Time in hours
70
60
50
40
30
R6
R7
20
10
0
0
10
20
Time in hours
30
88
2.5
Oral solution
1.5
0.5
10
20
30
Time in hours
CONCLUSION
NLTIOG could demonstrate to be useful substitutes to
oral formulations. The NLTIOG showed six-fold
increase in bioavailability of the drug than oral
solution. The NLTIOG of acyclovir were prepared
with P188/P407 and carbopol 940 showed drug release
up to 62.31% release for 24 hours. These NLTIOG are
liquid at room temperature and undergo gelation when
in contact with body temperature. All the optimized
formulae found to have less gelation time, excellent
spreadability and gelation capacity with human
physiological temperature.
REFERENCES
[1]
T Tran, JD Druce, MC Catton, H Kelly, CJ
Birch. Changing epidemiologyof genital
herpes simplex virus infection in Melbourne,
Australia, between1980 and 2003. Sex Transm
Infect. 2004, 80:277-9.
[2]
DH Emmert. Treatment of common cutaneous
Herpes Simplex Virus infections. Am Fam
Physician. 2000, 61:1697-704.
[3]
AG Wagstaff, D Faulds, KL Goa. Aciclovir: A
reappraisal
of
its
antiviral
activity,
pharmacokinetic properties and therapeutic
efficacy. Drugs, 1994,47:153-205.
[4]
M Ruhnese, F Sandstorm, B Andersson.
Treatment of recurrent genital herpes simplex
89
[5]
[6]
[7]
[8]
[9]
[10]
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
90